Report : Asia Pacific Epilepsy Drugs Market Forecast to 2030 - Regional Analysis - by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others)
At 4.6% CAGR, the Asia Pacific Epilepsy Drugs Market is Speculated to be Worth US$ 3,143.44 million by 2030, Says Business Market Insights
According to Business Market Insights research, the Asia Pacific epilepsy drugs market was valued at US$ 2,198.72 million in 2022 and is expected to reach US$ 3,143.44 million by 2030, registering a CAGR of 4.6% from 2022 to 2030. Increasing number of elderly people and increasing product approvals are among the critical factors attributed to the Asia Pacific epilepsy drugs market expansion.
Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise. Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.
On the contrary, recall of therapeutic products hampers the growth Asia Pacific epilepsy drugs market.
Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held 42.6% share of the Asia Pacific epilepsy drugs market in 2022, amassing US$ 936.96 million. It is projected to garner US$ 1,386.74 million by 2030 to expand at 5.0% CAGR during 2022-2030.
Based distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held 51.0% share of the Asia Pacific epilepsy drugs market in 2022, amassing US$ 1,122.17 million. It is projected to garner US$ 1,551.95 million by 2030 to expand at 4.1% CAGR during 2022-2030.
Based on country, the Asia Pacific epilepsy drugs market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 22.9% share of Asia Pacific epilepsy drugs market in 2022, amassing US$ 502.64 million. It is projected to garner US$ 746.31 million by 2030 to expand at 5.1% CAGR during 2022-2030.
Key players operating in the Asia Pacific epilepsy drugs market are Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd, among others.
- In January 2023; Pfizer Inc expanded its commitment to An Accord for a Healthier World. An Accord for a Healthier World is an initiative launched in May 2022 to reduce health inequities existing between many lower-income countries and the rest of the world. Pfizer Inc will offer its complete product portfolio of medicines and vaccines for 1.2 billion people living in 45 lower-income countries.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com